Biohaven Therapeutics Ltd.
Clinical trials sponsored by Biohaven Therapeutics Ltd., explained in plain language.
A biopharmaceutical company focused on neuroscience and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug taldefgrobep alfa enters Mid-Stage trial Results expected Sep 2026 (estimated) May already have reported ↗
- New pill aims to tame seizures in Drug-Resistant epilepsy Results expected Oct 2026 (estimated) May already have reported ↗
- New hope for rare burning pain: drug trial targets genetic cause Results expected Nov 2026 (estimated) May already have reported ↗
- New epilepsy drug shows promise in reducing seizures Results expected Dec 2026 (estimated) May already have reported ↗
- New epilepsy drug safety check: 660 patients monitored long-term Results expected Dec 2026 (estimated) May already have reported ↗
-
New depression pill shows promise in Long-Term safety check
Disease control CompletedThis study looked at the long-term safety of a new daily medication called BHV-7000 for people with major depressive disorder. A total of 233 adults who had already completed an earlier study took the pill once a day. Researchers tracked side effects, lab results, and heart chang…
Phase 2 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill aims to tame mania in bipolar disorder
Disease control CompletedThis study tested whether a new drug called BHV-7000 can safely and effectively treat manic episodes in people with bipolar I disorder. 274 hospitalized adults took either the drug or a placebo once daily for 21 days. The main goal was to see if the drug reduced mania symptoms, m…
Phase 2/3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New migraine pill shows promise in large trial
Symptom relief CompletedThis study tested an experimental drug called BHV-2100 for quickly stopping migraine pain and related symptoms like nausea or sensitivity to light. About 647 people with migraines took either the drug or a placebo. The goal was to see if the drug could provide pain relief within …
Phase 2 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
New depression pill shows promise in Mid-Stage trial
Symptom relief CompletedThis study tested whether a new drug called BHV-7000 can safely reduce depression symptoms in adults with moderate to severe major depressive disorder. About 336 participants took either the drug or a placebo for 6 weeks, and doctors measured changes using a standard depression r…
Phase 2 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC